Management Team

The Klotho Therapeutics (KTI) team is committed to commercializing Klotho protein and facilitating healthier aging for all. Led by founder James Plante, a serial healthcare/technology entrepreneur with several successful biotech exits, KTI operates virtually with a highly experienced team of subject matter experts.


Founder, Chairman & CEO

Jim is a serial entrepreneur and investor ( and has achieved many successful financial exits. He has a personal interest in making Klotho development successful as he suffers from Polycystic Kidney Disease, a genetic disorder that usually requires kidney transplantation.  Jim also established the Foundation for Kidney Transplant Research to further development of a cure ( In addition to founding and leading KTI, Jim is Founder and Chairman of Pathway Genomics ( Jim’s father died of cancer, a disease that appears to respond favorably to Klotho.

Dinesh Raturi, MD

VP Operations

Dinesh has over 16 years experience in the development process and manufacturing for proteins mAb’s, hormones and enzyme therapeutics.  He has developed over 100 proteins, many of which progressed to human trials.

William Ramage, DPhil

Chief Development Officer

Bill was formerly Vice President Corporate Development at DuPont Merck and Molecular Biosystems.  Bill is expert in corporate strategy and business development, with a 30+  year track record of executive leadership for biotech and pharma companies.  He has raised over $500 million through venture capital, M&A, IPO, private equity and licensing transactions.

Joe Tarsio, PhD, MBA


Joe is a 30 year veteran of pharmaceutical R&D with extensive project management and QA/QC experience with Charles River Labs and Bristol Meyers Squibb. He has developed several commercial therapeutic proteins including Belatacept and Orencia.

Debra Richardson, PhD


Debra brings over 25 years of patent strategy and internal IP management experience with startup and mid-stage biotechs to Klotho Therapeutics. Her expertise centers on licensing/sale, IPO, reverse merger and acquisition experience at Sequenom and Isis Pharmaceuticals.

Medical Advisory Board

The company is also well supported by an advisory board of the world’s leading clinicians and entrepreneurs including the discoverer of Klotho protein and gene and others skilled in commercialization, the biotech industry and kidney disease.

Makoto Kuro-O, MD PhD

Discovered Klotho protein/gene and is the world’s leading expert
(UT Southwestern Medical Center)

Eleanor D. Lederer, MD, FASN

Professor of Medicine, University of Louisville

Rinaldo Bellomo, MD

World leading expert in managing acute kidney disease in the ICU
(University of Melbourne, Australia)

Ming Chang Hu, MD Phd

Leading expert in animal research focused on the role of Klotho in acute kidney injury and chronic kidney disease (UT Southwestern Medical Center)

Orson Moe, MD

Leading expert in the role of Klotho to affect various disease states
(UT Southwestern Medical Center)

Christian Faul, Ph.D.

Associate Professor of Medicine and Cell Biology, University of Alabama

Gregory Stein, MD, MBA

AKI expert, CEO/Founder Curtana Pharma, formerly founder SOVA Parma for kidney disease, recently awarded Orphan drug status by FDA

Timothy Wright, MD

EVP Translational Sciences, CA Institute for Biomedical Research and was the former Global Head of Pharma Development at Novartis and  Director at Pfizer

Strategic Advisors

Edward Truitt

CEO/Founder Lubris Biopharmaceuticals, which recently announced a $1B license deal with Novartis for their recombinant therapeutic protein.

Gregory Gorgas, MBA

Strategic Marketing expert, CEO/Founder Artelo, formerly with Biogen IDEC

Robert Morlock, PhD

Healthcare outcomes expert, formerly with Biogen, Pfizer, Astra Zeneca

Killu Sanborn, PhD

Finance expert, Senior Director, Oxford Finance, formerly with Stratagene